药物洗脱微球经导管动脉化疗栓塞术治疗肝细胞癌进展  

Progresses of drug-eluting bead transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma

作　　者：邓国瑜 马亦龙[1] 赵昌[1] DENG Guoyu;MA Yilong;ZHAO Chang(Department of Intervention,Affiliated Tumor Hospital of Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学附属肿瘤医院介入科,广西南宁530021

出　　处：《中国医学影像技术》2020年第11期1730-1733,共4页Chinese Journal of Medical Imaging Technology

基　　金：广西医疗卫生适宜技术开发推广应用项目(S2017092);广西壮族自治区卫生健康委员会自筹经费科研课题(Z20190664)。

摘　　要：肝细胞癌(HCC)是最常见的原发性肝癌之一。经导管动脉化疗栓塞术(TACE)一直被用为中期HCC患者的一线治疗方法,而药物洗脱微球TACE(DEB-TACE)的临床应用近年来亦不断增加。本文对DEB-TACE的药物代谢动力学、微球选择、适应证和禁忌证及疗效评估进展进行综述。Hepatocellular carcinoma(HCC)is one of the most common primary liver carcinoma.Transcatheter arterial chemoembolization(TACE)has been used as the first-line treatment for patients with mid-term HCC.In recent years,clinical application of drug-eluting bead TACE(DEB-TACE)kept increasing.The pharmacokinetics,selection of microspheres,indications,contraindications and evaluation on therapeutic effect of DEB-TACE for treatment of HCC were reviewed in this article.

关 键 词：癌 肝细胞 化学栓塞 治疗性 

分 类 号：R735.7[医药卫生—肿瘤] R815[医药卫生—临床医学]